- Biomarkers form basis of blood-based ColonSentry(TM) test -
TORONTO, April 14 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported positive performance results from a large validation study of a six-gene biomarker panel for the assessment of a patient's current risk for colorectal cancer. This panel forms the basis of the Company's lead product, ColonSentry(TM), which is planned for launch in Canada in the third quarter of 2008 as a laboratory-developed test.
The validation study confirmed (p less than 0.05) that the panel was
able to stratify a population with average risk for colorectal cancer into
- Increased Probability: 18% of the population were defined as having a
3-fold increased probability of currently having colorectal cancer.
- Average Probability: 20% were defined as having an average probability
of currently having colorectal cancer.
- Decreased Probability: 62% were defined as having a 4-fold decreased
probability of currently having colorectal cancer.
"There is a need for a patient friendly test that can assess an
individual's current risk for colorectal cancer, thereby enabling average
risk patients to be stratified into more defined groups. This
stratification would facilitate shared decision-making by physicians and
their patients around screening options," commented Dr. Bernard Levin, an
internationally recognized expert in colorectal cancer screening. "Although
colorectal cancer can often be cured if detected early by screening, the
majority of individuals do not comply willingly with screening
recommendations because they find the screening methods such as stool tests
or invasive endoscopic or radiologic procedures to be unpleasant or
inconvenient. A blood test is more familiar and based on risk
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved